Comparison of BiomeOne and PD-L1 expression tests as a predictor for response to immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Robinson, I. [1 ]
Hochmair, M. J. [1 ]
Ay, L. [1 ]
Absenger, G. [2 ]
Jansen, C. [3 ]
Pacifico, C. [3 ]
Sladek, B. [3 ]
Knabl, A. [3 ]
Gasche, N. [3 ]
Valipour, A. [1 ]
机构：
[1] Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria
[2] Graz Univ Klin Innere Med, LKH Univ Klinikum, Graz, Austria
[3] Biome Diagnost GmbH, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2022.09.056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55P
引用
收藏
页码：S1400 / S1400
页数：1
相关论文
共 50 条
  • [41] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [42] Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC)
    Cardona, A. F.
    Arrieta, O.
    Ruiz-Patino, A.
    Zatarain Barron, L.
    Corrales-Rodriguez, L.
    Martin, C.
    Barron, F.
    Sotelo, C.
    Rodriguez, J.
    Ricaurte, L.
    Freitas, H.
    Cordeiro De Lima, V. C.
    Mas, L.
    Avila, J.
    Mayorga, D.
    Archila, P.
    Otero, J.
    Carranza, H.
    Vargas, C.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1171 - S1171
  • [43] Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
    Kim, Hyojin
    Choi, Sangjoon
    Kim, Seokhwi
    Aum, Jaehong
    Pereira, Sergio
    Park, Seonwook
    Ma, Minuk
    Shin, Seunghwan
    Paeng, Kyunghyun
    Yoo, Donggeun
    Jung, Wonkyung
    Ock, Chan-Young
    Lee, Se-Hoon
    Chung, Jin-haeng
    Choi, Yoon-La
    Mok, Tony S. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] PD-L1, brain metastases, and survival among patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
    Feisal, James
    Balakrishna, Pragathi
    Itani, Aleena
    King, Caleb
    Acharya, Pawan
    Vesely, Sara
    Aljumaily, Raid
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
    Yang, Qiao
    Chen, Mingjing
    Gu, Jiaoyang
    Niu, Kai
    Zhao, Xianlan
    Zheng, Linpeng
    Xu, Zihan
    Yu, Yongxin
    Li, Feng
    Meng, Lingxin
    Chen, Zhengtang
    Zhuo, Wenlei
    Zhang, Luping
    Sun, Jianguo
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [46] PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
    Jiang, Liyan
    Su, Xinying
    Zhang, Tianwei
    Yin, Xiaolu
    Zhang, Meizhuo
    Fu, Haihua
    Han, Hulin
    Sun, Yun
    Dong, Lili
    Qian, Jialin
    Xu, Yanhua
    Fu, Xuan
    Gavine, Paul R.
    Zhou, Yanbin
    Tian, Kun
    Huang, Jiaqi
    Shen, Dong
    Jiang, Haiyi
    Yao, Yihong
    Han, Baohui
    Gu, Yi
    ONCOTARGET, 2017, 8 (16) : 26845 - 26857
  • [47] The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression
    Ochi, Nobuaki
    Ichihara, Eiki
    Takigawa, Nagio
    Harada, Daijiro
    Inoue, Koji
    Shibayama, Takuo
    Hosokawa, Shinobu
    Kishino, Daizo
    Harita, Shingo
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 73 - 81
  • [48] PD-L1 Expression and CD8 Positive T Cell Tumor Infiltrate Level Predict Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Rosainz, Manuel Arana
    Gayhart, Matthew
    Chaum, Manita
    Eno, Celeste
    Song, Jianbo
    Medeiros, Fabiola
    Vail, Eric
    Lopategui, Jean
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1089 - 1090
  • [49] TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
    Cao, Xiaobo
    Zhao, Yang
    Wang, Jing
    Dai, Bingbing
    Gentile, Emanuela
    Lin, Jing
    Pu, Xingxiang
    Ji, Lin
    Wu, Shuhong
    Meraz, Ismail
    Majidi, Mourad
    Roth, Jack A.
    ONCOTARGET, 2017, 8 (64) : 107621 - 107629
  • [50] Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Nojima, Yuji
    Shimizu, Katsuhiko
    Saisho, Shinsuke
    Maeda, Ai
    Kurosaki, Takeshi
    Kurose, Koji
    Oga, Toru
    Oka, Mikio
    Nakata, Masao
    ANTICANCER RESEARCH, 2021, 41 (11) : 5469 - 5475
12345